Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclobenzaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.93 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.93 |
| ▸ | HRH1 | P35367 | 8/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.93 |
| ▸ | HTR2B | P41595 | 6/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.93 |
| ▸ | DRD2 | P14416 | 6/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.93 |
| ▸ | DRD3 | P35462 | 6/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.93 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.93 |
| ▸ | HTR1A | P08908 | 5/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.93 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.93 |
| ▸ | MTOR | P42345 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobenzaprine SCHEMBL29520569 | 0.97 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL38527 | 0.97 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL7654526 | 0.97 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29350662 | 0.95 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4964925 | 0.95 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL41376 | 0.95 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4606463 | 0.93 | LMNA (0.97) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL17812696 | 0.89 | HRH1 (0.84) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29015268 | 0.88 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL8892591 | 0.88 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11598774-B2 | Methods of diagnosis and treatment of Alzheimer's Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| CN-113624892-A | Method for detecting toxic impurities in cyclobenzaprine hydrochloride | 南通联亚药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20200088724-A1 | METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190336490-A1 | COMPOSITIONS AND METHODS FOR INCREASING REMYELINATION | Frequency Therapeutics, Inc. | 2019-11-07 | — | — | US | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| WO-2018081085-A1 | METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-03 | — | — | WO | disclosed |
| US-8629135-B2 | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-01-14 | — | — | US | disclosed |
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | GUJRAL, TARANJIT S. | 2011-08-18 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | HTR2A 209/4885HTR2C 222/4885HRH1 1292/4885 |
| US-20110201598-A1 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer | RET, THRB, SKP1 | HTR2A 1578/4885HTR2C 2019/4885HRH1 106/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2A 143/4885HTR2C 107/4885HRH1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.